Share General Information
Octreotide acetate is the current primary treatment for patients with acromegaly, together with other somatostatin analogue, Lanreotide.
About the API
Therapeutic category
Endocrinology
Available formulations
Injectables
Injectables Long-Acting
Regulations
-
Japan DMF
-
Korea DMF
-
US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
